Morgan Stanley Starts C4 Therapeutics (CCCC) at Underweight

Morgan Stanley analyst Terence Flynn initiates coverage on C4 Therapeutics (NASDAQ: CCCC) with a Underweight rating and a price target of $6.00.

For an analyst ratings summary and ratings history on C4 Therapeutics click here. For more ratings news on C4 Therapeutics click here.

Shares of C4 Therapeutics closed at $7.73 yesterday.

You May Also Be Interested In

• C4 Therapeutics, Inc. (CCCC) Tops Q2 EPS by 3c
• BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
• Leerink Starts Ligand Pharma (LGND) at Outperform